Supernus Pharmaceuticals (SUPN) Liabilities and Shareholders Equity (2011 - 2026)

Supernus Pharmaceuticals has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $1.4 billion in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $1.4 billion, up 3.31% year-over-year; the trailing twelve-month figure through Jun 2026 was $5.8 billion (up 6.63% YoY), and the FY2025 annual result was $1.5 billion, up 6.18% from the prior year.
• Liabilities and Shareholders Equity eased to $1.4 billion in Q2 2026, from $1.5 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.8 billion in Q1 2023 and troughed at $1.3 billion in Q4 2023.
• A 5-year average of $1.5 billion and a median of $1.4 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2024, when Liabilities and Shareholders Equity retreated 27.22%; it then climbed 11.39% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.7 billion in 2022, then retreated by 24.95% to $1.3 billion in 2023, then rose by 7.08% to $1.4 billion in 2024, then grew by 6.18% to $1.5 billion in 2025, then slipped by 1.69% to $1.4 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.4 billion in Q2 2026, $1.5 billion in Q1 2026, and $1.5 billion in Q4 2025.